Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant

Yamasoba, Daichi; Uriu, Keiya; Plianchaisuk, Arnon; Kosugi, Yusuke; Pan, Lin; Zahradník, Jiří; Ito, Jumpei; Sato, Kei

doi:10.1016/s1473-3099(23)00278-5

Cited by 123 publications

(92 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data is therefore available and not of a confidential nature. Ryan Varghese 1,2,3 Sanidhya Pai 2,3,4 Dileep Kumar 1,5,6 Rohit Sharma 7 1…”

Section: Conflict Of Interest Statementmentioning

confidence: 99%

“…Furthermore, XBB.1.16 has an effective reproductive number (R e ) 1.27-and 1.17-fold higher than the previous XBB.1 and XBB.1.5 variants, respectively, suggesting higher infectivity and transmissibility rates. 2 Recent reports suggest that the XBB.1.16 variant demonstrated robust neutralization resistance against variants such as BA.5 (37-times vs. B.1.1) and BA.2 (18times vs. B.1.1). 2 This suggests a conspicuous immune evasion property of XBB.1.16, compared with its parental variants.…”

mentioning

confidence: 99%

“…2 Recent reports suggest that the XBB.1.16 variant demonstrated robust neutralization resistance against variants such as BA.5 (37-times vs. B.1.1) and BA.2 (18times vs. B.1.1). 2 This suggests a conspicuous immune evasion property of XBB.1.16, compared with its parental variants. 8 This immune-evasiveness could be attributed to differences in its antigenicity compared to XBB.1.5 as well as nonspike protein mutations which expedite the viral growth rate.…”

mentioning

confidence: 99%

“…8 This immune-evasiveness could be attributed to differences in its antigenicity compared to XBB.1.5 as well as nonspike protein mutations which expedite the viral growth rate. 2 These factors have added to the virulence of its strain, and though not very significant, it is approximately 1.2 times more infectious than the XBB.1.5 variant. 3 While these results suggest a greater infectivity and pathogenicity than its previous strains 3 ; its epidemiological impact remains to be studied further.…”

mentioning

confidence: 99%

“…The mitigation steps including travel restrictions, mandatory masks, sanitization, continuous surveillance and monitoring, and rapid testing methods can be institutionalized. Additionally, polypills, repurposing of antivirals such as Sotrovimab,2 and the testtrack-treat-vaccinate strategy could help in curtailing the virus spread.…”

mentioning

confidence: 99%

See 4 more Smart Citations

SARS‐CoV‐2 XBB.1.16 variant: India in focus?

Varghese

Pai

Kumar

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

However, the recent surge in cases has been precipitated by a novel Omicron XBB.1.16 variant, dubbed "Arcturus." 3 First detected from samples collected in January 2023, XBB.1.16 4 has rapidly spread to over 31 countries by late March 2023, 5 and is reported to have originated in India, where it is predominant and has replaced other strains of the virus. 3,6,7 Cases have also been reported in several parts of Europe, and countries such as Australia, Britain, Brunei (4.50%), 5 Canada, India (highest number of sequences globally at 32.47%), 5 Indonesia, Singapore (3.21%), 5 and the United States. [6][7][8][9] In the United States, the cases caused by XBB.1.16 strain sore from 0.21% in late February, to 3.96% in March, and 7.2% in mid-April 2023. 6 Owing to such an increase in cases, on March 22, 2023, the World Health Organization (WHO) designated XBB.1.16 as a variant under monitoring status, and later as a variant of interest on April 17, 2023. 5 Nextstrain/Nextclade has promoted XBB.1.16 as a novel clade, 23B. 5 Currently, XBB.1.16 is one of the seven variants of SARS-CoV-2 currently being monitored. 6 Compared with the parental XBB.1.5 variant that bore the spike protein mutation, F486P, XBB.1.16 variant presents two additional mutations, viz. E180V and T478R, 2 as illustrated in

show abstract

“…The data is therefore available and not of a confidential nature. Ryan Varghese 1,2,3 Sanidhya Pai 2,3,4 Dileep Kumar 1,5,6 Rohit Sharma 7 1…”

Section: Conflict Of Interest Statementmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

SARS‐CoV‐2 XBB.1.16 variant: India in focus?

Varghese

Pai

Kumar

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity

Zhou

Zhi

Teng

2022

Journal of Medical Virology

114

View full text Add to dashboard Cite

As of November 2021, several SARS‐CoV‐2 variants appeared and became dominant epidemic strains in many countries, including five variants of concern (VOCs) Alpha, Beta, Gamma, Delta, and Omicron defined by the World Health Organization during the COVID‐19 pandemic. As of August 2022, Omicron is classified into five main lineages, BA.1, BA.2, BA.3, BA.4, BA.5 and some sublineages (BA.1.1, BA.2.12.1, BA.2.11, BA.2.75, BA.4.6) ( https://www.gisaid.org/ ). Compared to the previous VOCs (Alpha, Beta, Gamma, and Delta), all the Omicron lineages have the most highly mutations in the spike protein, and with 50 mutations accumulated throughout the genome. Early data indicated that Omicron BA.2 sublineage had higher infectivity and more immune escape than the early wild‐type (WT) strain, the previous VOCs, and BA.1. Recently, global surveillance data suggest a higher transmissibility of BA.4/BA.5 than BA.1, BA.1.1 and BA.2, and BA.4/BA.5 is becoming dominant strain in many countries globally.

show abstract